Terms: = Liver cancer AND AFP, AFPD, FETA, HPAFP AND Treatment
2080 results:
1. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy of microwave ablation with parallel acupuncture guided by ultrasound in treating single hepatocellular carcinoma in high-risk areas: A retrospective analysis of 155 patients.
Liu S; Zhou P; Shen Q; Qian G
J Cancer Res Ther; 2024 Apr; 20(2):547-554. PubMed ID: 38687924
[TBL] [Abstract] [Full Text] [Related]
3. Current Roles of Ramucirumab in the Sequential treatment of Unresectable Hepatocellular Carcinoma.
Koizumi A; Komatsu S; Omiya S; Yano Y; Fujishima Y; Ishida J; Kido M; Gon H; Fukushima K; Urade T; So S; Yoshida T; Arai K; Fujinaka R; Shimura Y; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2024 May; 44(5):2055-2061. PubMed ID: 38677746
[TBL] [Abstract] [Full Text] [Related]
4. Therapeutic Management and Outcomes of Hepatoblastoma in a Pediatric Patient with Mosaic Edwards Syndrome.
Sosnowska-Sienkiewicz P; Kamińska A; Anderko I; Telman-Kołodziejczyk G; Mańkowski P; Januszkiewicz-Lewandowska D
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674397
[TBL] [Abstract] [Full Text] [Related]
5. Alpha-fetoprotein: Past, present, and future.
Yeo YH; Lee YT; Tseng HR; Zhu Y; You S; Agopian VG; Yang JD
Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38619448
[TBL] [Abstract] [Full Text] [Related]
6. Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors.
Yang LM; Wang HJ; Li SL; Gan GH; Deng WW; Chang YS; Zhang LF
World J Gastroenterol; 2024 Mar; 30(11):1533-1544. PubMed ID: 38617449
[TBL] [Abstract] [Full Text] [Related]
7. Tyrosine hydroxylase inhibits HCC progression by downregulating TGFβ/Smad signaling.
Liu G; Li M; Zeng Z; Fan Q; Ren X; Wang Z; Sun Y; He Y; Sun L; Deng Y; Liu S; Zhong C; Gao J
Eur J Med Res; 2024 Apr; 29(1):228. PubMed ID: 38610044
[TBL] [Abstract] [Full Text] [Related]
8. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
Ohama H; Hiraoka A; Tada T; Hirooka M; Kariyama K; Hatanaka T; Tani J; Takaguchi K; Atsukawa M; Itobayashi E; Nishimura T; Tsuji K; Tajiri K; Ishikawa T; Yasuda S; Toyoda H; Fukunishi S; Ogawa C; Kakizaki S; Shimada N; Naganuma A; Kawata K; Kosaka H; Kuroda H; Matono T; Yata Y; Ochi H; Tada F; Nouso K; Morishita A; Itokawa N; Okubo T; Arai T; Tsutsui A; Nagano T; Yokohama K; Nishikawa H; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; Kumada T;
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2042. PubMed ID: 38577725
[TBL] [Abstract] [Full Text] [Related]
9. The Utility of Serum Alpha-fetoprotein for Monitoring for Relapse of Alpha-fetoprotein-Positive Hepatoblastoma.
Davini M; Hastings C; Feusner J
J Pediatr Hematol Oncol; 2024 May; 46(4):206-210. PubMed ID: 38551915
[TBL] [Abstract] [Full Text] [Related]
10. Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma.
Hou C; Xiong B; Zhou L; Fei Y; Shi C; Zhu X; Xie T; Wu Y
BMC Cancer; 2024 Mar; 24(1):387. PubMed ID: 38539150
[TBL] [Abstract] [Full Text] [Related]
11. Surgical Intervention After Lenvatinib treatment in Patients With Advanced Hepatocellular Carcinoma.
Okuno M; Hatano E; Tada M; Nishimura T; Okamoto T; Sueoka H; Iida K; Nakamura I; Iijima H; Hirono S
Anticancer Res; 2024 Apr; 44(4):1727-1737. PubMed ID: 38537993
[TBL] [Abstract] [Full Text] [Related]
12. Portable photoelectrochemical immunoassay with micro-electro-mechanical-system for alpha-fetoprotein in hepatocellular carcinoma.
Lou F; Wang S; Han B; Li Q; Tang D
Anal Chim Acta; 2024 Apr; 1298():342411. PubMed ID: 38462335
[TBL] [Abstract] [Full Text] [Related]
13. Clinical outcomes of percutaneous microwave ablation for pulmonary oligometastases from hepatocellular carcinoma: a retrospective, multicenter study.
Wang G; Wei Z; Wang F; Han X; Jia H; Zhao D; Li C; Liu L; Yang X; Ye X
Cancer Imaging; 2024 Mar; 24(1):34. PubMed ID: 38438879
[TBL] [Abstract] [Full Text] [Related]
14. Serum alpha-fetoprotein response as a preoperative prognostic indicator in unresectable hepatocellular carcinoma with salvage hepatectomy following conversion therapy: a multicenter retrospective study.
Lin KY; Zhang JX; Lin ZW; Chen QJ; Luo LP; Chen JH; Wang K; Tai S; Zhang ZB; Wang SF; Li JD; Wang K; Zheng L; Zheng SM; Wu MM; Lin KC; Yang T; Zeng YY
Front Immunol; 2024; 15():1308543. PubMed ID: 38433845
[TBL] [Abstract] [Full Text] [Related]
15. Construction of web
Zhan G; Cao P; Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 48(10):1546-1560. PubMed ID: 38432884
[TBL] [Abstract] [Full Text] [Related]
16. Development and evaluation of nomograms and risk stratification systems to predict the overall survival and cancer-specific survival of patients with hepatocellular carcinoma.
Kang X; Liu X; Li Y; Yuan W; Xu Y; Yan H
Clin Exp Med; 2024 Feb; 24(1):44. PubMed ID: 38413421
[TBL] [Abstract] [Full Text] [Related]
17. An AgPd NP-based lateral flow immunoassay for simultaneous detection of glycocholic acid and alpha-fetoprotein.
Jiang S; Chen Y; Liang J; Xiao H; Lin M; Cui X; Zhao S
Anal Methods; 2024 Mar; 16(10):1508-1514. PubMed ID: 38372146
[TBL] [Abstract] [Full Text] [Related]
18. Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.
Zhang L; Sun T; Sun B; Zhang K; Zheng Y; Li N; Chen L; Zheng C; Liang B; Shi H
BMC Cancer; 2024 Feb; 24(1):223. PubMed ID: 38365678
[TBL] [Abstract] [Full Text] [Related]
19. GenX caused liver injury and potential hepatocellular carcinoma of mice via drinking water even at environmental concentration.
Wan G; Zhang Z; Chen J; Li M; Li J
Environ Pollut; 2024 Apr; 346():123574. PubMed ID: 38365076
[TBL] [Abstract] [Full Text] [Related]
20. Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma.
Chen A; Yu Z; Ma N; Lu X; Zhang Y; Xu W; Wang Y; Xie J; Qin Y; Mo G; Wu S; Hou J; Zhu W
Cancer Immunol Immunother; 2024 Feb; 73(3):49. PubMed ID: 38349553
[TBL] [Abstract] [Full Text] [Related]
[Next]
